公司資料
Fortress Biotech 股價、新聞與催化劑
- 股票代碼:
- FBIO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.77 USD (-2.81%)
收盤價
最後更新: 2026年8月20日
88M USD
市值
股價為何變動
As of Aug 20, 2026, FBIO closed down 2.81% at $2.77. No new same-company headline was identified in the current news window.
公司概覽
Multi-Asset Biopharmaceutical Holding Company
Fortress Biotech creates value by acquiring, forming, and advancing biopharmaceutical businesses and assets. Its portfolio includes commercial prescription products, development-stage programs, controlled subsidiaries, and minority investments across oncology, dermatology, and rare diseases.
Decentralized Company-Building Model
Fortress frequently places individual assets within focused subsidiaries that can raise capital, form partnerships, or pursue strategic transactions independently. The parent company retains value through equity ownership, royalties, milestones, and other contractual economics.
Rare Disease and Commercial Assets
Subsidiary Cyprium obtained FDA approval for ZYCUBO in Menkes disease and monetized the associated Rare Pediatric Disease Priority Review Voucher. Following Sun Pharma’s acquisition of Checkpoint, Fortress retains long-term royalty exposure to UNLOXCYT.
Multiple Monetization Pathways
Fortress can realize value through commercial product revenue, subsidiary transactions, priority review vouchers, royalties, milestone payments, and retained equity interests. This structure means portfolio value may be created through regulatory success or strategic transactions at individual subsidiaries.
Partnership-Sourced Pipeline
Fortress sources programs through collaborations with organizations including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber, and Sentynl. Avenue’s acquisition of ATX-04 from Duke University adds a clinically validated program in Pompe disease.
未來催化劑
- Triplex clinical data in patients co-infected with HIV and cytomegalovirus by the end of 2026.
- Initiation of the MB-109 study in recurrent glioblastoma and high-grade astrocytoma in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。